
News|Articles|December 8, 2010
ASH 2010 Homepage Header
Advertisement
Oncology NEWS International reports on critical information from the American Society of Hematology's 52nd annual meeting.
- Rituximab instead of ‘watch and wait’ policy in asymptomatic follicular lymphoma causes controversy
- Ofatumumab generates high response rates in refractory CLL
- Industry update: Early-stage trials establish pathways for new treatment agents
- More Coverage from ASH 2010
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Five Gastrointestinal Cancer Abstracts You May Have Missed at ESMO GI 2026
2
TOP Trial: Chemo-Osimertinib in TP53-Mutant EGFR-Mutated NSCLC
3
How Are CELMoDs Reshaping Treatment in Multiple Myeloma?
4
Epcoritamab/R2 Earns European Approval for R/R Follicular Lymphoma
5
















































































